Old Web
PIN28 A US Payer Cost-Effectiveness Analysis of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients with Carbapenem-Resistant Bacterial Infections
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI